View Exam | PowerPak

1. Which of the following statements best describes the presenting clinical features for a newly diagnosed patient with myelodysplastic syndrome?

A. A 25-year-old patient with fevers, night sweats, and lymphadenopathy B. A 42-year-old patient with persistently elevated white blood cell count and normal blood cell differential C. A 59-year-old patient with severe anemia, thrombocytopenia, and a white blood cell count above 100,000mm3 D. A 72-year-old patient who is anemic with white blood cell and platelet counts that are low/normal E. Unsure

2. Which of the following treatment modalities is the best first-line treatment for a newly diagnosed 75-year-old patient with low-risk myelodysplastic syndrome and multiple medical comorbidities?

A. Azacitidine B. Allogeneic hematopoietic stem cell transplantation C. Epoetin alfa D. Antithymocyte globulin and cyclosporine E. Unsure

3. A patient has low-risk myelodysplastic syndrome with ringed sideroblasts and an isolated anemia. They are receiving ESA therapy but have increasing transfusion requirements. Which of the following treatment options is most appropriate?

A. Luspatercept B. Lenalidomide C. Azacitidine and venetoclax D. Cytarabine and daunorubicin E. Unsure

4. Which of the following therapeutic strategies is most appropriate for patients that have the 5q- cytogenetic abnormality?

A. Decitabine/cedazuridine B. Lenalidomide C. Azacitidine D. Monthly red blood cell transfusions E. Unsure

5. Which of the following patients with myelodysplastic syndrome would benefit most from iron chelation therapy?

A. Low-risk patient on surveillance with no transfusion history B. Low-risk patient on erythropoiesis-stimulating agent therapy and a history of 1 or 2 transfusions yearly C. Low-risk patient on erythropoiesis-stimulating agent therapy and a monthly transfusion requirement D. Newly diagnosed patient with tri-lineage dysplasia about to receive induction chemotherapy with cytarabine and daunorubicin E. Unsure

Evaluation Questions

6. How confident are in your treatment choice for the patients presented in the posttest?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements best describes the presenting clinical features for a newly diagnosed patient with myelodysplastic syndrome?

2. Which of the following treatment modalities is the best first-line treatment for a newly diagnosed 75-year-old patient with low-risk myelodysplastic syndrome and multiple medical comorbidities?

3. A patient has low-risk myelodysplastic syndrome with ringed sideroblasts and an isolated anemia. They are receiving ESA therapy but have increasing transfusion requirements. Which of the following treatment options is most appropriate?

4. Which of the following therapeutic strategies is most appropriate for patients that have the 5q- cytogenetic abnormality?

5. Which of the following patients with myelodysplastic syndrome would benefit most from iron chelation therapy?

Evaluation Questions

6. How confident are in your treatment choice for the patients presented in the posttest?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements best describes the presenting clinical features for a newly diagnosed patient with myelodysplastic syndrome?

2. Which of the following treatment modalities is the best first-line treatment for a newly diagnosed 75-year-old patient with low-risk myelodysplastic syndrome and multiple medical comorbidities?

3. A patient has low-risk myelodysplastic syndrome with ringed sideroblasts and an isolated anemia. They are receiving ESA therapy but have increasing transfusion requirements. Which of the following treatment options is most appropriate?

4. Which of the following therapeutic strategies is most appropriate for patients that have the 5q- cytogenetic abnormality?

5. Which of the following patients with myelodysplastic syndrome would benefit most from iron chelation therapy?

Evaluation Questions

6. How confident are in your treatment choice for the patients presented in the posttest?

« Return to Activity

Customers who Purchased
this Activity also Purchased